Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Alterations of the arginine metabolome in sickle cell disease: a growing rationale for arginine therapy.

Morris CR.

Hematol Oncol Clin North Am. 2014 Apr;28(2):301-21. doi: 10.1016/j.hoc.2013.11.008. Review.

PMID:
24589268
2.

Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.

Okam MM, Ebert BL.

Expert Rev Hematol. 2012 Jun;5(3):303-11. doi: 10.1586/ehm.12.20. Review.

PMID:
22780210
3.

Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.

Iyamu EW, Cecil R, Parkin L, Woods G, Ohene-Frempong K, Asakura T.

Br J Haematol. 2005 Nov;131(3):389-94.

PMID:
16225659
4.

Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea.

Nahavandi M, Tavakkoli F, Wyche MQ, Perlin E, Winter WP, Castro O.

Br J Haematol. 2002 Dec;119(3):855-7.

PMID:
12437671
5.

Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea.

Green NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, Clark LN, Manwani D, Crotty J, Kisselev S, Neville KA, Hoppe C, Barral S.

PLoS One. 2013;8(2):e55709. doi: 10.1371/journal.pone.0055709. Epub 2013 Feb 7.

6.

Hydroxyurea therapy in children severely affected with sickle cell disease.

Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.

J Pediatr. 1996 Jun;128(6):820-8.

PMID:
8648542
7.

Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?

Morris CR, Morris SM Jr, Hagar W, Van Warmerdam J, Claster S, Kepka-Lenhart D, Machado L, Kuypers FA, Vichinsky EP.

Am J Respir Crit Care Med. 2003 Jul 1;168(1):63-9. Epub 2003 Mar 5.

PMID:
12626350
8.

[How I treat ... sickle cell anemia: current therapies].

Rezaei Kalantari H.

Rev Med Liege. 2001 Oct;56(10):671-5. Review. French.

PMID:
11765575
9.

Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.

Hoppe C, Vichinsky E, Quirolo K, van Warmerdam J, Allen K, Styles L.

J Pediatr Hematol Oncol. 2000 Jul-Aug;22(4):330-4.

PMID:
10959903
10.

Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.

Jain DL, Sarathi V, Desai S, Bhatnagar M, Lodha A.

Hemoglobin. 2012;36(4):323-32. doi: 10.3109/03630269.2012.697948.

PMID:
22734586
11.

Use of hydroxyurea in children with sickle cell disease: what comes next?

Ohene-Frempong K, Smith-Whitley K.

Semin Hematol. 1997 Jul;34(3 Suppl 3):30-41. Review.

PMID:
9317199
12.

The role of the arginine metabolome in pain: implications for sickle cell disease.

Bakshi N, Morris CR.

J Pain Res. 2016 Mar 30;9:167-75. doi: 10.2147/JPR.S55571. eCollection 2016. Review.

13.

Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease.

Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB.

Ann Intern Med. 2008 Jun 17;148(12):939-55. Epub 2008 May 5. Review.

14.

Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy.

Little JA, Hauser KP, Martyr SE, Harris A, Maric I, Morris CR, Suh JH, Taylor J, Castro O, Machado R, Kato G, Gladwin MT.

Eur J Haematol. 2009 Apr;82(4):315-21. doi: 10.1111/j.1600-0609.2009.01210.x. Epub 2008 Feb 10.

16.

Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.

Ma Q, Wyszynski DF, Farrell JJ, Kutlar A, Farrer LA, Baldwin CT, Steinberg MH.

Pharmacogenomics J. 2007 Dec;7(6):386-94. Epub 2007 Feb 13.

PMID:
17299377
17.

Hydroxyurea and sickle cell disease: a chance for every patient.

Weiner DL, Brugnara C.

JAMA. 2003 Apr 2;289(13):1692-4. No abstract available.

PMID:
12672739
18.

Effect of hydroxyurea therapy on resting energy expenditure in children with sickle cell disease.

Fung EB, Barden EM, Kawchak DA, Zemel BS, Ohene-Frempong K, Stallings VA.

J Pediatr Hematol Oncol. 2001 Dec;23(9):604-8.

PMID:
11902305
19.

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Blood Cells Mol Dis. 2000 Oct;26(5):453-66.

PMID:
11112383
20.

[Hydroxyurea and other agents stimulating synthesis of fetal hemoglobin].

de Montalembert M.

Pathol Biol (Paris). 1999 Jan;47(1):55-8. Review. French.

PMID:
10081780

Supplemental Content

Support Center